3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
8
fludarabine phosphate
7
Peripheral Blood Stem Cell Transplantation
7
Mycophenolic Acid
6
Flow Cytometry
6
Whole-Body Irradiation
5
Therapeutics
5
Cyclosporine
5
Radiotherapy
4
Polymerase Chain Reaction
4
Busulfan
4
Antilymphocyte Serum
4
Vorinostat
3
Tacrolimus
3
Nivolumab
3
Methylprednisolone
3
Methotrexate
3
Immunoenzyme Techniques
3
Carboplatin
3
Amplified Fragment Length Polymorphism Analysis
3
Alemtuzumab
3
thymoglobulin
2
pembrolizumab
2
liposomal amphotericin B
2
durvalumab
2
Thiotepa
2
Sunitinib
2
Specimen Handling
2
Psychiatric Rehabilitation
2
Prednisone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
CLR1404
×
Genitourinary
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled